AcelRx

Impel NeuroPharma Announces Appointment Of Adrian Adams As Chairman Of The Board Of Directors | PR Newswire | 1/9/2020

… help build out the organization and drive these needed therapies forward to market.” Adrian graduated from the Royal Institute of Chemistry at Salford University in the U.K. and currently serves as Chairman for both AcelRx Pharmaceuticals and Akebia Therapeutics. About Impel NeuroPharma Impel NeuroPharma, Inc., is a privately-held, Seattle-based biopharmaceutical company focused on developing transformative therapies for people living with central nervous system (CNS) disorders that unlock the …

Analysts’ Downgrades for January, 8th (AAXN, ACRS, ACRX, ADAP, ADRZY, AGLE, ALBO, ALDX, AMADY, AMRS) | 1/9/2020

… ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “ Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Adaptimmune Therapeutics plc is …

Follow AcelRx:    

AcelRx Pharmaceuticals (NASDAQ:ACRX) Upgraded to “Buy” at ValuEngine - Transcript Daily | 1/8/2020

ValuEngine upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a hold rating to a buy rating in a research note released on Saturday morning, ValuEngine reports. Several other analysts also recently commented on ACRX. Credit Suisse Group downgraded shares of AcelRx Pharmaceuticals from an outperform rating to a neutral rating and decreased their price objective for the company from $7.00 to $2.00 in a research report on Monday, November 11th …

AcelRx Pharmaceuticals (NASDAQ:ACRX) Downgraded by Zacks Investment Research to “Hold” | Daily Political | 1/8/2020

… ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “A number of other research analysts also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of …

ValuEngine Upgrades AcelRx Pharmaceuticals (NASDAQ:ACRX) to “Buy” | 1/7/2020

ValuEngine upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a hold rating to a buy rating in a research note published on Saturday, ValuEngine reports. Other equities research analysts also recently issued reports about the company. HC Wainwright reiterated a buy rating and issued a $9.00 price objective on shares of AcelRx Pharmaceuticals in a report on Friday, November 8th. Credit Suisse Group downgraded AcelRx Pharmaceuticals from an outperform rating …

AcelRx Pharmaceuticals (NASDAQ:ACRX) Lifted to Buy at ValuEngine | 1/5/2020

AcelRx Pharmaceuticals (NASDAQ:ACRX) Lifted to Buy at ValuEngine Posted by Stuart Ham on Jan 5th, 2020 Tweet ValuEngine upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a hold rating to a buy rating in a report issued on Saturday, ValuEngine reports. A number of other research firms also recently issued reports on ACRX. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a hold rating to a strong-buy …

Research Analysts’ Upgrades for January, 4th (AAVVF, ACRX, AT, BANF, BFS, CATY, CCUR, CHDN, CHMA, CHTR) | 1/4/2020

Research Analysts’ upgrades for Saturday, January 4th: Advantage Oil & Gas (OTCMKTS:AAVVF) was upgraded by analysts at ValuEngine from a strong sell rating to a sell rating. Get Advantage Oil & Gas Ltd alerts: AcelRx Pharmaceuticals (NASDAQ:ACRX) was upgraded by analysts at ValuEngine from a hold rating to a buy rating. Atlantic Power (NYSE:AT) (TSE:ATP) was upgraded by analysts at ValuEngine from a sell rating to a hold …

AcelRx Pharmaceuticals (NASDAQ:ACRX) Rating Increased to Buy at ValuEngine - Ticker Report | 1/4/2020

AcelRx Pharmaceuticals (NASDAQ:ACRX) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” report issued to clients and investors on Saturday, ValuEngine reports. Several other analysts also recently weighed in on ACRX. Zacks Investment Research raised AcelRx Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $2.25 target price for the company in a report on Monday, November 11th. Credit Suisse Group …

Top Ranked Momentum Stocks to Buy for January 3rd - January 3, 2020 - Zacks.com | 1/3/2020

… last 60 days. Mobile TeleSystems PJSC Price and Consensus Mobile TeleSystems Public Joint Stock’s shares gained 10.1% over the last one month. The company possesses a Momentum Score of B. Mobile TeleSystems PJSC Price AcelRx Pharmaceuticals, Inc. ( ACRX - Free Report ) : This specialty pharmaceutical company has a Zacks Rank 1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 12.7% over the last 60 days. AcelRx Pharmaceuticals, Inc …

AcelRx Pharmaceuticals (ACRX) Upgraded to Strong Buy: What Does It Mean for the Stock? | Yahoo News | 1/3/2020

AcelRx Pharmaceuticals (ACRX) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks Equity Research Reblog AcelRx Pharmaceuticals (ACRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank 1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates – one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company’s changing …

AcelRx Pharmaceuticals (ACRX) Upgraded to Strong Buy: What Does It Mean for the Stock? - January 3, 2020 - Zacks.com | 1/3/2020

… make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time. Therefore, the Zacks rating upgrade for AcelRx Pharmaceuticals basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Most Powerful Force Impacting Stock Prices The change in a company’s future earnings potential …

Top Ranked Momentum Stocks to Buy for January 3rd - January 3, 2020 - Zacks.com | 1/3/2020

… Report ) : This specialty pharmaceutical company has a Zacks Rank 1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 12.7% over the last 60 days. AcelRx Pharmaceuticals, Inc. Price and Consensus AcelRx Pharmaceuticals, Inc. price-consensus-chart AcelRx Pharmaceuticals, Inc. Quote AcelRx Pharmaceuticals’ shares gained 15% over the last one month. The company possesses a Momentum Score of B. AcelRx Pharmaceuticals, Inc. Price AcelRx Pharmaceuticals, Inc. price …

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Shares Bought by State Street Corp | 1/1/2020

State Street Corp raised its holdings in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) by 10.4% during the third the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,403,576 shares of the specialty pharmaceutical company’s stock after buying an additional 132,409 shares during the period. State Street Corp owned about 1.76% of AcelRx Pharmaceuticals worth $3,088,000 SEC filing. Other institutional investors …

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Receives Consensus Rating of “Buy” from Brokerages | 1/1/2020

… to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $6.46. A number of brokerages have commented on ACRX. Credit Suisse Group lowered AcelRx Pharmaceuticals from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $7.00 to $2.00 in a report on Monday, November 11th. HC Wainwright reissued a “buy” rating and …

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Receives Consensus Recommendation of “Buy” from Analysts | 1/1/2020

… the stock in the last year is $6.46. A number of research firms have recently weighed in on ACRX. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of AcelRx Pharmaceuticals in a report on Friday, November 8th. Credit Suisse Group downgraded shares of AcelRx Pharmaceuticals from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $7.00 to …

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Shares Bought by State Street Corp - Ticker Report | 1/1/2020

State Street Corp raised its holdings in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) by 10.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,403,576 shares of the specialty pharmaceutical company’s stock after buying an additional 132,409 shares during the period. State Street Corp owned about 1.76% of AcelRx Pharmaceuticals worth $3,088,000 as of …

How Much Are AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Insiders Spending On Buying Shares? | 12/30/2019

NexTech (OTC: NEXCF) Signs Multi-Platform AR Deal With Medical Device Manufacturer Sterilis Solutions December 17, 2019 Comments Off on NexTech (OTC: NEXCF) Signs Multi-Platform AR Deal With Medical Device Manufacturer Sterilis Solutions …

Brokerages Set AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) PT at $6.46 - Ticker Report | 12/30/2019

Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) have been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the firm, Marketbeat reports. Three investment analysts have hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last …

AcelRx Pharmaceuticals (NASDAQ:ACRX) Shares Down 6.7% | 12/29/2019

… A decline of 49% from the average daily volume of 1,447,232 shares. The stock had previously closed at $2.40. ACRX has been the subject of several research reports. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $2.25 target price for the company in a report on Monday, November 11th. HC Wainwright restated a “buy” rating and issued a …

AcelRx Pharmaceuticals (NASDAQ:ACRX) Trading Down 6.7% | 12/29/2019

Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) dropped 6.7% during trading on Friday . The stock traded as low as $2.22 and last traded at $2.24, approximately 740,452 shares were traded during mid-day trading. A decline of 49% from the average daily volume of 1,447,232 shares. The stock had previously closed at $2.40. ACRX has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued …

Biotech

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks’ Positive Readout, Enanta Misses Earnings Estimate | Benzinga | 11/22/2019

Here’s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals … Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed …

AcelRx Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? | Zacks | 11/13/2019

… follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article AcelRx Pharmaceuticals, Inc. ( ACRX - Free Report ) ) has been struggling lately, but the selling pressure may … of today’s Zacks 1 Rank (Strong Buy) stocks here . Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands …

Pain Management

Dr. TJ Gan to Present at the 2019 Annual Meeting of the American Society of Anesthesiologists | PR Newswire | 10/16/2019

REDWOOD CITY, Calif. , AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming presentation at the Annual Meeting of the American Society of Anesthesiologists. Dr. Gan will present and lead a discussion around acute pain and an alternative approach to pain management. Patients often report moderate-to-severe pain following procedures …

Dr. TJ Gan to Present at the 2019 Annual Meeting of the American Society of Anesthesiologists | Business & Finance | heraldchronicle.com | PR Newswire | 10/16/2019

REDWOOD CITY, Calif., Oct. 16, 2019 /PRNewswire/ – AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming presentation at the Annual Meeting of the American Society of Anesthesiologists. Dr. Gan will present and lead a discussion around acute pain and an alternative approach to pain management. Patients often report moderate-to …

Pain Management

Dr. TJ Gan to Present at the 2019 Annual Meeting of the American Society of Anesthesiologists | Business & Finance | heraldchronicle.com | PR Newswire | 10/16/2019

REDWOOD CITY, Calif., Oct. 16, 2019 /PRNewswire/ – AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming presentation at the Annual Meeting of the American Society of Anesthesiologists. Dr. Gan will present and lead a discussion around acute pain and an alternative approach to pain management. Patients often report moderate-to …

Pain Treatment

AcelRx Pharmaceuticals: Extremely Promising Risk/Reward Profile - AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) | Seeking Alpha | 10/16/2019

… for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » AcelRx Pharmaceuticals ( ACRX ) offers opioid-based medication for acute moderate-to-severe pain. Its stock … designed for usage in supervised medical facilities and for acute pain treatment only - in other words, they should not be left outside the current opioid crisis discussion that relates to chronic pain treatment based on …

After Years Of Development, AcelRx’s Dsuvia Has Finally Generated Revenue - AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) | Seeking Alpha | 5/16/2019

Last week, on Wednesday, May 8, AcelRx (NASDAQ: ACRX ) reported its financial results from the first quarter of 2019 . Though there has not been a huge amount of news to report since the company’s last … who visit the ER and receive an IV exclusively for pain treatment. Source: AcelRx March 2019 Investor Presentation AcelRx’s first step in reaching its target market is through winning formulary approvals, and the company projects …

Clinical Research

Dr. TJ Gan to Present at the 2019 Annual Meeting of the American Society of Anesthesiologists | Business & Finance | heraldchronicle.com | PR Newswire | 10/16/2019

REDWOOD CITY, Calif., Oct. 16, 2019 /PRNewswire/ – AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an … Dr. Gan was Professor of Anesthesiology and Vice Chairman for Clinical Research and Faculty Development at Duke University. Dr. Gan received his medical training at the London Hospital Medical College of the University of London …

ACO

AcelRx Pharmaceuticals Inc (ACRX) Q2 2019 Earnings Call Transcript | Yahoo News | 8/6/2019

Logo of jester cap with thought bubble. More Image source: The Motley Fool. AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) Q2 2019 Earnings Call Aug 5, 2019 , 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call … Medical Officer. Also with us today is an anesthesiologist, Dr. Jacob Hutchins, who will share his experience with using DSUVIA in the University of Minnesota Ambulatory Surgery Center. Before we begin, I’ll remind listeners that …

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/6/2019

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) Q 2, 2019 Earnings Conference Call August 5, 2019 5:00 PM ET CompanyParticipants Vince Angotti - Chief Executive Officer Raffi Asadorian - Chief Financial Officer Pam Palmer - Chief Medical Officer and Co-Founder Jacob Hutchins - Anesthesiologist and Associate Professor, Department of Anesthesiology Conference CallParticipants Brandon Folkes - Cantor Fitzgerald Randall Stanicky - RBC Capital Markets Ed Arce - H.C. Wainwright Chris Howerton - Jefferies Andrew D’Silva - B Riley FBR Michael Higgins …

Food and Drug Administration

3 Stocks Peter Lynch Would Love | Yahoo News | 4/29/2019

… three of our Motley Fool contributors to provide a quick rundown for their top Peter Lynch-like picks. They named AcelRx Pharmaceuticals (NASDAQ: ACRX) , Teladoc (NYSE: TDOC) , and Bristol-Myers Squibb (NYSE: BMY) . Read on … cut benefits over injectable pain relievers, Dsuvia’s approval by the Food and Drug Administration late last year was met by a wave of criticism from industry experts and caregivers alike. The key concern is that …

Medical Research

AcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain | PR Newswire | 11/16/2017

AcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain News provided by 07:00 ET Share this article REDWOOD CITY, Calif. , Nov. 16, 2017 /PRNewswire/ – AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX … and Rehabilitative Medicine Research Program (CRMRP) of the U.S. Army Medical Research and Materiel Command (USAMRMC) under contract No. W81XWH-15-C-0046. The CRMRP was established in 2008 to foster research and technology advances …

AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department | PR Newswire | 11/9/2017

AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department News provided by 07:00 ET Share this article REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire … and Rehabilitative Medicine Research Program (CRMRP) of the U.S. Army Medical Research and Materiel Command (USAMRMC) under contract No. W81XWH-15-C-0046. The CRMRP was established in 2008 to foster research and technology advances …

Pfizer

Neurological Disorder Drugs Market Active Status, Growth Opportunities, Forecast to 2027 – Neurocrine Biosciences, Pfizer, Biogen, Teva, AcelRx, Eli Lilly, Adamas, BioMarin, AstraZeneca, Novartis | 12/3/2019

Press Releases Neurological Disorder Drugs Market Active Status, Growth Opportunities, Forecast to 2027 – Neurocrine Biosciences, Pfizer, Biogen, Teva, AcelRx, Eli Lilly, Adamas, BioMarin, AstraZeneca, Novartis Neurological Disorders are associated with dysfunction in any part of the brain or nervous system resulting in physical or psychological damage. Various types of neurological drugs are available in the market such as antipsychotic, antiepileptic, anticholinergic and analgesics for the treatments of neurological disorders. The …

Worldwide Generics Market Forecasts to 2030 with Focus on Value-Added Medicines/Supergenerics - Policy Changes, Increasing Competition & Price Erosion Challenges the Market | Globe Newswire | 11/8/2019

… 13 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION 3M 3SBio Abon Pharmaceuticals Abraxis BioScience (a subsidiary of Celgene) Accord Healthcare AcelRx Pharmaceuticals Aclaris Therapeutics Acorda Therapeutics Acrotech Biopharma ACS Dobfar Actavis (a subsidiary of Teva … Sterile Products (a subsidiary of Par Pharmaceutical) Pearl Therapeutics Perrigo Pfizer Pharmadax PLx Pharma Praxair ProSolus Provepharm Life Solutions Raptor Pharmaceuticals Recordati Rempex Pharmaceuticals Rising Pharmaceuticals Rosemont Pharmaceuticals Roxane Laboratories (a subsidiary of Hikma Pharmaceuticals …

Neurocrine Biosciences

Neurological Disorder Drugs Market Active Status, Growth Opportunities, Forecast to 2027 – Neurocrine Biosciences, Pfizer, Biogen, Teva, AcelRx, Eli Lilly, Adamas, BioMarin, AstraZeneca, Novartis | 12/3/2019

Press Releases Neurological Disorder Drugs Market Active Status, Growth Opportunities, Forecast to 2027 – Neurocrine Biosciences, Pfizer, Biogen, Teva, AcelRx, Eli Lilly, Adamas, BioMarin, AstraZeneca, Novartis Neurological Disorders are associated with dysfunction in any part of the brain or nervous system resulting in physical or psychological damage. Various types of neurological drugs are available in the market such as antipsychotic, antiepileptic, anticholinergic and analgesics for the treatments of neurological disorders. The …

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical’s Earnings Beat | Benzinga | 11/12/2019

… Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 11) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX )(Credit Suisse downgraded shares to Neutral) Achieve Life Sciences Inc (NASDAQ: ACHV ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Applied DNA Sciences Inc (NASDAQ: APDN ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) ( reported a negative clinical readout) Assertio Therapeutics Inc (NASDAQ …

Rockwell Medical

Peoples Bancorp of North Carolina, Inc. (PEBK): Hedge Funds Watching From Afar | Yahoo News | 11/24/2019

Rockwell Medical Inc (NASDAQ: RMTI ), Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ), and AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) to get a better sense of its popularity. Video: Click the image to watch our video about the top 5 most popular hedge fund stocks. More So, why do we pay attention to hedge fund sentiment before making any investment decisions? Our research has shown that hedge funds’ small-cap stock picks managed to …

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs | Benzinga | 11/7/2019

… 3) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 6) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) AVEO Pharmaceuticals, Inc. (NASDAQ … Oyster Point Pharma Inc (NASDAQ: OYST ) (IPOed on Oct. 31) Rockwell Medical Inc (NASDAQ: RMTI ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) Supernus Pharmaceuticals Inc (NASDAQ: SUPN )( announced a negative clinical readout for ADHD drug and disappointing …

Celgene

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks’ Positive Readout, Enanta Misses Earnings Estimate | Benzinga | 11/22/2019

… ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM … Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed …

Worldwide Generics Market Forecasts to 2030 with Focus on Value-Added Medicines/Supergenerics - Policy Changes, Increasing Competition & Price Erosion Challenges the Market | Globe Newswire | 11/8/2019

… Celgene) Accord Healthcare AcelRx Pharmaceuticals Aclaris Therapeutics Acorda Therapeutics Acrotech Biopharma ACS Dobfar Actavis (a subsidiary of Teva Pharmaceutical) Adamis Pharmaceuticals ADDMEDICA ADIENNE Aegis Therapeutics Ailex Pharmaceuticals Akorn Alcon Alembic Pharmaceuticals Allergan ALRISE Biosystems Altaire Pharmaceuticals Altus Formulation Alyvant American Regent Amerigen Pharmaceuticals Amneal Pharmaceuticals ANI Pharmaceuticals Antares Pharma Apotex Aprecia Pharmaceuticals Armstrong Pharmaceuticals Ascendia Pharmaceuticals Ascendis Pharma Assertio Therapeutics AstraZeneca Aurobindo Pharma Avadel Pharmaceuticals Avanir Pharmaceuticals Avedro Avion Pharmaceuticals …

Amgen

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks’ Positive Readout, Enanta Misses Earnings Estimate | Benzinga | 11/22/2019

… Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene … Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed …

SunTrust sees 16% upside in Amgen in premarket analyst action - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) | Seeking Alpha | 11/12/2019

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Buy rating and $125 (15% upside) price target at SunTrust. Amgen (NASDAQ: AMGN ) initiated with Buy rating and $256 (16% upside) price target at SunTrust. Arcus Biosciences (NYSE: RCUS … with an $8 (14% downside risk) price target at JPMorgan. AcelRx Pharmaceuticals (NASDAQ: ACRX ) downgraded to Neutral with a $2 (12% upside) price target at Credit Suisse. Shares up 3% premarket. Amneal Pharmaceuticals (NYSE: AMRX …

Allergan

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical’s Earnings Beat | Benzinga | 11/12/2019

… for developing it as a combo therapay along with Urogen’s UGN-201 for high-grade non-muscle invasive bladder cancer) Allergan plc (NYSE: AGN ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Cabaletta Bio Inc (NASDAQ: CABA ) Centogene … Dumps (Biotech stocks hitting 52-week lows on Nov. 11) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX )(Credit Suisse downgraded shares to Neutral) Achieve Life Sciences Inc (NASDAQ: ACHV ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Applied DNA …

Worldwide Generics Market Forecasts to 2030 with Focus on Value-Added Medicines/Supergenerics - Policy Changes, Increasing Competition & Price Erosion Challenges the Market | Globe Newswire | 11/8/2019

AcelRx Pharmaceuticals Aclaris Therapeutics Acorda Therapeutics Acrotech Biopharma ACS Dobfar Actavis (a subsidiary of Teva Pharmaceutical) Adamis Pharmaceuticals ADDMEDICA ADIENNE Aegis Therapeutics Ailex Pharmaceuticals Akorn Alcon Alembic Pharmaceuticals Allergan ALRISE Biosystems Altaire Pharmaceuticals Altus Formulation Alyvant American Regent Amerigen Pharmaceuticals Amneal Pharmaceuticals ANI Pharmaceuticals Antares Pharma Apotex Aprecia Pharmaceuticals Armstrong Pharmaceuticals Ascendia Pharmaceuticals Ascendis Pharma Assertio Therapeutics AstraZeneca Aurobindo Pharma Avadel Pharmaceuticals Avanir Pharmaceuticals Avedro Avion Pharmaceuticals B. Braun Bausch …

Vertex Pharmaceuticals

SunTrust sees 16% upside in Amgen in premarket analyst action - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) | Seeking Alpha | 11/12/2019

Vertex Pharmaceuticals (NASDAQ: VRTX ) initiated with Buy rating and $235 (16% upside) price target at SunTrust. Teva Pharmaceutical Industries (NYSE: TEVA ) upgraded to Neutral with an $8 (14% downside risk) price target at JPMorgan. AcelRx Pharmaceuticals (NASDAQ: ACRX ) downgraded to Neutral with a $2 (12% upside) price target at Credit Suisse. Shares up 3% premarket. Amneal Pharmaceuticals (NYSE: AMRX ) downgraded to Underweight at JPMorgan. Shares down 3% premarket. Cellular Biomedicine …

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek’s Mixed Clinical Readout, CareDx Slips On Guidance | Benzinga | 11/1/2019

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX )(reacted to third-quarter results) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Oct. 31) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO )(reported below-consensus third-quarter earnings) Alimera Sciences Inc (NASDAQ: ALIM ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) Cerus Corporation (NASDAQ: CERS )(reacted to third-quarter results) Cocrystal Pharma …

Bristol-Myers Squibb

Worldwide Generics Market Forecasts to 2030 with Focus on Value-Added Medicines/Supergenerics - Policy Changes, Increasing Competition & Price Erosion Challenges the Market | Globe Newswire | 11/8/2019

… 13 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION 3M 3SBio Abon Pharmaceuticals Abraxis BioScience (a subsidiary of Celgene) Accord Healthcare AcelRx Pharmaceuticals Aclaris Therapeutics Acorda Therapeutics Acrotech Biopharma ACS Dobfar Actavis (a subsidiary of Teva … Serums and Vaccines BioDelivery Sciences International Birdie Pharmaceuticals Bracco Braeburn Bristol-Myers Squibb BWX Technologies Celator Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals) Celgene Cellix Bio Celltrion Healthcare Chiesi Farmaceutici Cintex Cipla CMP Pharma Cocoon Biotech …

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek’s Mixed Clinical Readout, CareDx Slips On Guidance | Benzinga | 11/1/2019

… Stocks Hitting 52-week highs on Oct. 31) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) AstraZeneca plc (NYSE: AZN ) Bristol-Myers Squibb Co (NYSE: BMY )( reported better-than-expected third-quarter results) Celgene Corporation … Dumps (Biotech Stocks Hitting 52-week lows on Oct. 31) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO )(reported below-consensus third-quarter earnings) Alimera Sciences Inc (NASDAQ …

Merck

Worldwide Generics Market Forecasts to 2030 with Focus on Value-Added Medicines/Supergenerics - Policy Changes, Increasing Competition & Price Erosion Challenges the Market | Globe Newswire | 11/8/2019

… 13 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION 3M 3SBio Abon Pharmaceuticals Abraxis BioScience (a subsidiary of Celgene) Accord Healthcare AcelRx Pharmaceuticals Aclaris Therapeutics Acorda Therapeutics Acrotech Biopharma ACS Dobfar Actavis (a subsidiary of Teva … Pharmaceuticals Mallinckrodt Pharmaceuticals Mayne Pharma Medesis Pharma MedinCell Medline Industries Merck Meridian Medical Technologies Micelle BioPharma Mikart Mipharm Mithra Pharmaceuticals MSN Laboratories Mylan Nanocopoeia NanoVelos Natco Pharma NAVINTA Neos Therapeutics Nesher Pharmaceuticals Neurelis Nexus Pharmaceuticals …

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs | Benzinga | 11/7/2019

… 3) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 6) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) AVEO Pharmaceuticals, Inc. (NASDAQ … Nosiblan is an oral oxycontin receptor antagonist licensed from Germany’s MERCK KGAA/S ADR (OTC: MKKGY ). The company has decided to discontinue the current development of nolasiban for IVF and will explore potential repositioning of …

GlaxoSmithKline

Worldwide Generics Market Forecasts to 2030 with Focus on Value-Added Medicines/Supergenerics - Policy Changes, Increasing Competition & Price Erosion Challenges the Market | Globe Newswire | 11/8/2019

… 13 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION 3M 3SBio Abon Pharmaceuticals Abraxis BioScience (a subsidiary of Celgene) Accord Healthcare AcelRx Pharmaceuticals Aclaris Therapeutics Acorda Therapeutics Acrotech Biopharma ACS Dobfar Actavis (a subsidiary of Teva … Pharmaceuticals Fresenius Kabi Galderma General Atlantic Genus Lifesciences Gland Pharma GlaxoSmithKline Glenmark Pharmaceuticals GP Pharm Handa Pharmaceuticals Hanmi Pharmaceutical HANSAmed HealthCare Royalty Partners Heron Therapeutics Hetero Horizon Therapeutics Hospira HQ Speciality Pharma Hyundai Bioscience IBSA …

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek’s Mixed Clinical Readout, CareDx Slips On Guidance | Benzinga | 11/1/2019

… Holdings AG Basel ADR Common Stock (OTC: RHHBY )) Dova Pharmaceuticals Inc (NASDAQ: DOVA ) GENMAB A/S/S ADR (NASDAQ: GMAB ) GlaxoSmithKline plc (NYSE: GSK ) Oyster Point Pharma Inc (NASDAQ: OYST ) (IPOed Thursday) Rapt Therapeutics Inc … Dumps (Biotech Stocks Hitting 52-week lows on Oct. 31) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO )(reported below-consensus third-quarter earnings) Alimera Sciences Inc (NASDAQ …

RBC Capital Markets

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/6/2019

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) Q 2, 2019 Earnings Conference Call August 5, 2019 5:00 PM ET CompanyParticipants Vince Angotti - Chief Executive Officer Raffi Asadorian - Chief Financial Officer Pam Palmer - Chief Medical Officer and Co-Founder Jacob Hutchins - Anesthesiologist and Associate Professor, Department of Anesthesiology Conference CallParticipants Brandon Folkes - Cantor Fitzgerald Randall Stanicky - RBC Capital Markets Ed Arce - H.C. Wainwright Chris Howerton - Jefferies Andrew D’Silva - B Riley FBR Michael Higgins …

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/9/2019

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Chief Medical Officer Conference Call Participants Dan Busby - RBC Capital Markets Brandon Folkes - Cantor Fitzgerald Vamil Divan - Credit Suisse Michael Higgins - Ladenburg Thalman Andrew D’Silva - B Riley FBR Aryeh Gold - Oppenheimer Operator Welcome to the AcelRx First Quarter 2019 Conference …

Viscogliosi Brothers

PDL BioPharma’s Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide | PR Newswire | 11/8/2017

AcelRx, University of Michigan , Viscogliosi Brothers and Depomed. PDL’s equity and loan investments in Noden represent deployed and committed capital of $179.0 million and $202.0 million , respectively, and its converted equity and loan investment in LENSAR represents deployed capital of $40 million . NOTE: PDL, PDL BioPharma, the PDL logo and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary, to PDL BioPharma, Inc. which reserves all …

PDL BioPharma’s Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process | PR Newswire | 11/8/2017

AcelRx, University of Michigan , Viscogliosi Brothers and Depomed. PDL’s equity and loan investments in Noden represent deployed and committed capital of $179.0 million and $202.0 million , respectively, and its converted equity and loan investment in LENSAR represents deployed capital of $40 million . NOTE: PDL, PDL BioPharma, the PDL logo and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary, to PDL BioPharma, Inc. which reserves all …

Hennepin County Medical Center

AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department | PR Newswire | 11/9/2017

AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department News provided by 07:00 ET Share this article REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire … commented Dr. James Miner , Chief of Emergency Medicine at the Hennepin County Medical Center. “The use of sufentanil sublingual tablets is particularly promising as it could lead to more efficient acute pain treatment, thereby potentially …

Leiden University Medical Center

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … University Hospitals in Philadelphia, PA; Albert Dahan, MD, PhD, Professor, Leiden University Medical Center in Leiden, Netherlands; and Dennis Fisher, MD, Professor Emeritus, University of California, San Francisco. Time/Place: 6:30 am – 8:00 am on …

Pamela Palmer

AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg Tablets | PR Newswire | 11/13/2019

REDWOOD CITY, Calif. , Nov. 13, 2019 /PRNewswire/ – AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a publication … tablet has efficacy across all the demographic subgroups,” commented Dr. Pamela Palmer , AcelRx Chief Medical Officer. “An important reason behind the development of DSUVIA® was to avoid common opioid medication errors occurring with the clear …

AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg Tablets | Tri | wfmz.com | 11/13/2019

AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg Tablets By AcelRx Pharmaceuticals, Inc. AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.) By AcelRx Pharmaceuticals, Inc. Save … tablet has efficacy across all the demographic subgroups,” commented Dr. Pamela Palmer , AcelRx Chief Medical Officer. “An important reason behind the development of DSUVIA® was to avoid common opioid medication errors occurring with the clear …

Vince Angotti

AcelRx Pharmaceuticals Reports Third Quarter 2019 Financial Results | PR Newswire | 11/6/2019

REDWOOD CITY, Calif. , Nov. 6, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its third quarter 2019 financial results. “Achieving 125 REMS-certified facilities two months ahead of our year-end goal demonstrates healthcare providers’ increasing interest in DSUVIA,” said Vince Angotti , Chief Executive Officer of AcelRx. “We also expect to …

AcelRx Pharmaceuticals Reports Third Quarter 2019 Financial Results - GuruFocus.com | 11/6/2019

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its third quarter 2019 financial results. “Achieving 125 REMS-certified facilities two months ahead of our year-end goal demonstrates healthcare providers’ increasing interest in DSUVIA,” said Vince Angotti , Chief Executive Officer of AcelRx. “We also expect to achieve our year-end objective …

Jacob Hutchins

AcelRx Pharmaceuticals Inc (ACRX) Q2 2019 Earnings Call Transcript | Yahoo News | 8/6/2019

Logo of jester cap with thought bubble. More Image source: The Motley Fool. AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) Q2 2019 Earnings Call Aug 5, 2019 , 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call … Medical Officer. Also with us today is an anesthesiologist, Dr. Jacob Hutchins, who will share his experience with using DSUVIA in the University of Minnesota Ambulatory Surgery Center. Before we begin, I’ll remind listeners that …

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/6/2019

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) Q 2, 2019 Earnings Conference Call August 5, 2019 5:00 PM ET CompanyParticipants Vince Angotti - Chief Executive Officer Raffi Asadorian - Chief Financial Officer Pam Palmer - Chief Medical Officer and Co-Founder Jacob Hutchins - Anesthesiologist and Associate Professor, Department of Anesthesiology Conference CallParticipants Brandon Folkes - Cantor Fitzgerald Randall Stanicky - RBC Capital Markets Ed Arce - H.C. Wainwright Chris Howerton - Jefferies Andrew D’Silva - B Riley FBR Michael Higgins …

Randall Stanicky

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/6/2019

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) Q 2, 2019 Earnings Conference Call August 5, 2019 5:00 PM ET CompanyParticipants Vince Angotti - Chief Executive Officer Raffi Asadorian - Chief Financial Officer Pam Palmer - Chief Medical Officer and Co-Founder Jacob Hutchins - Anesthesiologist and Associate Professor, Department of Anesthesiology Conference CallParticipants Brandon Folkes - Cantor Fitzgerald Randall Stanicky - RBC Capital Markets Ed Arce - H.C. Wainwright Chris Howerton - Jefferies Andrew D’Silva - B Riley FBR Michael Higgins …

AcelRx Pharmaceuticals’ (ACRX) CEO Vince Angotti on Q3 2017 Results - Earnings Call Transcript | Seeking Alpha | 11/10/2017

AcelRx Pharmaceuticals’ (ACRX) CEO Vince Angotti on Q3 2017 Results - Earnings Call Transcript Nov. 9.17 AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) Q3 2017 Earnings Conference Call November 09, 2017 04:30 PM ET Executives Jane Wright-Mitchell - Chief Legal Officer Vince Angotti - CEO Pam Palmer - Chief Medical Officer Raffi Asadorian - CFO Randall Stanicky - RBC Capital Markets Michael Higgins - ROTH Capital Partners Ed Arce - H.C. Wainwright Operator Welcome to the AcelRx Third Quarter …

Peter Lynch

3 Stocks Peter Lynch Would Love | Yahoo News | 4/29/2019

Peter Lynch is widely regarded as one of the best investors of all time, and for good reason. During his 13-year tenure at the Fidelity Magellan Fund, Lynch grew a modest $20 million into … rundown for their top Peter Lynch-like picks. They named AcelRx Pharmaceuticals (NASDAQ: ACRX) , Teladoc (NYSE: TDOC) , and Bristol-Myers Squibb (NYSE: BMY) . Read on to find out more about these outstanding growth vehicles. A …

James Miner

AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department | PR Newswire | 11/9/2017

AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department News provided by 07:00 ET Share this article REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire … several limitations with the current treatment options available,” commented Dr. James Miner , Chief of Emergency Medicine at the Hennepin County Medical Center. “The use of sufentanil sublingual tablets is particularly promising as it could lead …

John P. McLaughlin

PDL BioPharma’s Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide | PR Newswire | 11/8/2017

… will not extend the deadline for, or otherwise alter, its proposal. In reaching the decision to not extend the deadline, John P. McLaughlin , chief executive officer of PDL, said, “We continue to believe our proposal … committed capital of $396.1 million and $397.1 million , respectively: KYBELLA®, AcelRx, University of Michigan , Viscogliosi Brothers and Depomed. PDL’s equity and loan investments in Noden represent deployed and committed capital of $179.0 million and $202.0 …

PDL BioPharma’s Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process | PR Newswire | 11/8/2017

… will not extend the deadline for, or otherwise alter, its proposal. In reaching the decision to not extend the deadline, John P. McLaughlin , chief executive officer of PDL, said, “We continue to believe our proposal … committed capital of $396.1 million and $397.1 million , respectively: KYBELLA®, AcelRx, University of Michigan , Viscogliosi Brothers and Depomed. PDL’s equity and loan investments in Noden represent deployed and committed capital of $179.0 million and $202.0 …

Karen DiDonato

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … Meeting. The information presented during the session was authored by Karen DiDonato , MSN, RN; Jacob Hutchins , MD; James Miner , MD; Harold Minkowitz , MD; and Pamela Palmer , MD, PhD. “We are honored to be one of …

Harold Minkowitz

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … Karen DiDonato , MSN, RN; Jacob Hutchins , MD; James Miner , MD; Harold Minkowitz , MD; and Pamela Palmer , MD, PhD. “We are honored to be one of the top eight abstracts featured as an oral presentation at …

Eugene Viscusi

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … of sublingual sufentanil tablets. This symposium will be led by Eugene Viscusi , MD; Albert Dahan , MD, PhD; and Dennis Fisher , MD. The ANESTHESIOLOGY ® 2017 Annual Meeting is hosted by the American Society of Anesthesiologists (ASA …